Although RIPK1 kinase inhibitors (Necrostatins) protects against TNF-induced SIRS [44, 48, 49], lipophilic radical traps such as ferrostatins or liproxstatins protect against AKI [47, 50]. This evidence concerns the gene RIPK1 and systemic inflammatory response syndrome.